Hodgkin Lymphoma News and Research

RSS

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Treatments for lymphoma with no side effects

Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.

2 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Study reveals underlying molecular mechanism contributing to development of lymphomagenesis

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults.

29 Nov 2011

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

EBV vaccine could prevent mononucleosis and cancers linked to virus

In a new article from the National Institutes of Health (NIH), Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Harold Varmus, M.D., director of the National Cancer Institute (NCI), join Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center, and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases, in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine.

3 Nov 2011

Study: Melanoma survivors more likely to have new cancers

Melanoma skin cancer survivors are much more likely than the general population to have future new cases of invasive melanomas and other cancers, says a national study led by UAMS' Appathurai Balamurugan, M.D., M.P.H.

3 Nov 2011

Solid organ transplant may increase risk of cancer

Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a study in the November 2 issue of JAMA.

2 Nov 2011

Diet, body weight in young adulthood associated with risk for NHL

Body weight in young adulthood and diet appeared to be associated with the risk for non-Hodgkin lymphoma, according to results presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011.

24 Oct 2011

Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion

Chronic fatigue syndrome (CFS) may be alleviated by the anti-cancer drug Rituximab, suggesting that the source of the disease could lie in the immune system, according to a new study published Oct. 19 in the online journal PLoS ONE.

20 Oct 2011

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

18 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug

A drug recently approved by the U.S. Food and Drug Administration for treatment of an adult cancer targets a malfunctioning gene discovered more than a decade earlier at St. Jude Children's Research Hospital. The story highlights how scientific findings from St. Jude can be translated into therapies and tests that in addition to helping children, also help adults.

30 Sep 2011

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Research in Switzerland could help reduce the time taken to develop vaccines against cancer tumours.

27 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Long-term effects of chemotherapy on women's reproductive health

Current estimates of the impact of chemotherapy on women's reproductive health are too low, according to a University of California, San Francisco (UCSF) study.

26 Aug 2011

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics, Inc. today announced that it has initiated a phase II clinical trial of ADCETRIS for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

24 Aug 2011

Hodgkin Lymphoma News and Research

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Treatments for lymphoma with no side effects

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

Study reveals underlying molecular mechanism contributing to development of lymphomagenesis

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pharmacyclics first quarter GAAP net loss increases to $14.5M

EBV vaccine could prevent mononucleosis and cancers linked to virus

Study: Melanoma survivors more likely to have new cancers

Solid organ transplant may increase risk of cancer

Diet, body weight in young adulthood associated with risk for NHL

Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

Long-term effects of chemotherapy on women's reproductive health

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Everything you should know about lymphoma eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News